Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junctionï¼Œa Phase II Clinical Study
The goal of this clinical trial is to find better protocal for adenocarcinoma of the gastric and gastroesophageal juncion.

The main question is aim to answer is:

1. The efficacy and safety of PD-1 monoclonal antibody (Sintilimab) combined with nab-paclitaxel and S-1 in the first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma.

Participants will be given PD-1 monoclonal antibody, nab-paclitaxel and tegio.
Gastric Cancer|GastroEsophageal Cancer|Adenocarcinoma
DRUG: Sintilimab,nab-paclitaxel and tegio
Progression free survival (PFS), Tumor assessment will be performed using radiography method every 6 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year|Objective response rate (ORR), Tumor assessment will be performed using radiography method every 6 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year
Overall survival (OS), Tumor assessment will be performed using radiography method every 6 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year|Disease control rate (DCR), Tumor assessment will be performed using radiography method every 6 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year|Disease control rate (DOR), Tumor assessment will be performed using radiography method every 6 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year
The goal of this clinical trial is to find better protocal for adenocarcinoma of the gastric and gastroesophageal juncion.

The main question is aim to answer is:

1. The efficacy and safety of PD-1 monoclonal antibody (Sintilimab) combined with nab-paclitaxel and S-1 in the first-line treatment of advanced gastric and gastroesophageal junction adenocarcinoma.

Participants will be given PD-1 monoclonal antibody, nab-paclitaxel and tegio.